CASE STUDY. Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk. Introduction.
|
|
- Audra Barker
- 5 years ago
- Views:
Transcription
1 CASE STUDY Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk Introduction Germline cancer risk assessment tests are well-prescribed tests from Strand Life Sciences. These lab-developed tests are designed to understand whether a person harbors mutated genes that can cause hereditary cancers. In India, there is a high proportion of hereditary breast and ovarian cancer (HBOC) cases, a fact that is evident from the high incidence of breast and ovarian cancers in women in their thirties (1,2). Hereditary cancers - about 10% of all cancer cases - develop at a young age and are typically more aggressive as well. One way to manage the disease efficiently is to understand one s own personal risk before the actual development and detection of cancer. Strand offers many germline tests to people who have been diagnosed with cancer. When such patients are found positive for an inherited mutation, Strand also offers Mutation-Specific Tests (MST) or follow up testing to first degree relatives (siblings, children and parents) or other affected members in the family to understand if they are carriers of the same inherited cancer-causing gene. MSTs are convenient because the turnaround is rapid and consequently, the cost of the test is also low. Patient Profile Adira Joseph*, a 55-year-old high school math teacher from Mumbai was diagnosed with ovarian cancer in Adira was shocked, naturally, upon receiving this diagnosis. She never imagined that cancer would become a part of her life, just when life was running smoothly on the home as well as career front. She had always been careful with health management and led an active lifestyle complemented with a good diet and moderate alcohol consumption. Adira was advised standard chemotherapy for ovarian cancer, as well as genetic testing to understand the cause of her ovarian cancer. Gender: Female, proband (mother) plus daughter Age: 44 years and 26 years Location: Mumbai, Maharashtra Diagnosis: Ovarian Cancer, Hereditary BOC syndrome suspected Strand Test: Strand Germline Cancer Test Conclusion: BRCA1 mutation identified in proband Eligibility for PARP inhibitor therapy established Prevalence of HBOC in family confirmed MST offered to proband s daughter Daughter is negative for the heritable BRCA1 mutation Adira had received chemotherapy for her ovarian cancer, in several rounds, for nearly eleven years. Her cancer would respond to the treatment initially, but would re-emerge a few months later. Since the cancer was persistent, her oncologist advised her to undergo genetic testing to identify the genetic cause of her ovarian cancer. Family History Adira s mother had been diagnosed with ovarian cancer at the age of 55 years. Her mother s sister had also suffered from ovarian cancer (age of diagnosis, 55 years). Adira s maternal uncle had battled throat cancer. Adira s sister had been diagnosed with blood cancer, at the age of 22 years. Adira s daughter was 28 years old and was unaffected, when Adira took the germline test. Given this family history of various cancers, inheritance of a cancer-causing gene mutation was strongly suspected. Accordingly, the Strand Hereditary Cancer Test for hereditary predisposition towards breast and ovarian cancer was prescribed to Adira. * Name changed to protect patient privacy
2 Family Tree - Pre-Test Genetic Counselling Adira was found to be Positive for a heterozygous 'pathogenic' variant, detected in an essential splice donor site at the junction of exon 16-intron 16 of the BRCA1 gene. BRCA1 chr17: c>t c.507+1g>a
3 Key Findings A pathogenic mutation in the BRCA1 gene was detected in Adira s genome. This mutation was at the splice site between exon 16 and intron 16 in the BRCA1 gene. Incorrect splicing of the BRCA1 mrna, owing to this mutation, was expected to create a frameshift mutation, leading to premature termination of the protein. The resultant BRCA1 protein would lack the BRCT2 domain that is engaged in DNA repair. Therefore, this loss-of-function variant of BRCA1 is the most probable genetic cause of Adira s ovarian cancer. Treatment Plan Generic chemotherapy would have been the therapy of choice for targeting Adira s ovarian cancer, if the germline analysis had not been done. However, the identification of the BRCA1 mutation in her DNA makes her eligible to receive PARP inhibitor therapy as well. Treatment of ovarian cancer patients with PARP inhibitors results in longer periods of progression-free survival in patients (3,4). Mutation-Specific Testing Adira was adamant that her 26-year-old daughter Pearl* be tested for the presence of the same BRCA1 mutation as well. Strand s genetic counsellor had explained the inheritance pattern of autosomal dominant mutations in genes such as BRCA1 and BRCA2 to her. She was aware that Pearl had a 50% chance of bearing the same mutation in her genome. Moreover, the counselor had stressed upon the fact that early identification of a woman s genetic status can lead to better health surveillance and better planning of motherhood. Also, Strand s MST tests are highly economical and simple. A small blood sample was all that Pearl had to provide to get her genome analyzed. MST was advised to Adira s younger daughters, aged 24 and 22 years, respectively, as well. The timing of the MST is just right for them since their BRCA status, if they are positive, can be leveraged to manage their decisions for having children. They can have children and then undergo risk-reduction surgery (removal of ovaries) that has a protective effect against ovarian cancer (5 7). Results of Mutation-Specific Testing The genetic variant identified in Adira s genome was NOT detected in Pearl s genome. Figure 1: Sanger sequencing data (electropherogram) from the individual showing the reference nucleotide 'G' at position c in the BRCA1 gene (RefSeq id:nm_007294). This finding was confirmed by sequencing with forward primer in two independent experiments. Therefore, Pearl is unlikely to suffer from hereditary breast and ovarian cancer, resulting from the hereditary mutation that Adira, her mother and presumably her aunt, also bear in their genomes. Pearl s risk for suffering from other cancers that can result as a function of having a BRCA1 mutation is also low (8,9).
4 Conclusions Adira, a 44-year-old woman from Mumbai, was diagnosed with ovarian cancer and was advised genetic testing. Adira s family history indicated a strong likelihood of hereditary breast and ovarian cancer in the family. The Strand Hereditary Cancer Test facilitated the identification of a BRCA1 mutation- chr17: c>t c g>a in Adira s DNA. Identification of this mutation indicates her eligibility to receive PARP inhibitor therapy instead of standard chemotherapy. Mutation-specific testing of Adira s daughter Pearl led to the confirmation that she had NOT inherited this pathogenic mutation. Adira and Pearl were counseled about their risks for developing other cancers (apart from breast and ovarian cancer) in their lifetime. Germline (proband) + MST (first degree relatives) tests are a good combination to rapidly assess the prevalence of hereditary cancer syndromes in families. Strand Hereditary Cancer Test The Strand Hereditary Cancer Test is designed to identify mutations in 19 genes that are involved in several inherited cancers. The following genes are analyzed in samples from breast and ovarian cancer patients, as per international genetic testing guidelines. ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53
5 References Mannan AU, Singh J, Lakshmikeshava R, Thota N, Singh S, Sowmya TS, et al. Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India. J Hum Genet [Internet]. 2016;61(6): Available from: Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol [Internet] Aug [cited 2017 Aug 16];13(4): Available from: Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med [Internet] Dec [cited 2017 Jan 16];375(22): Available from: Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol [Internet] Jan [cited 2017 Jan 21];18(1): Available from: Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, et al. Risk-reducing Salpingo Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. Anticancer Res [Internet] Sep 6 [cited 2017 Sep 12];37(9): Available from: Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, et al. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol [Internet] Nov [cited 2017 Sep 12];143(2): Available from: Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. J Gynecol Oncol [Internet] Jan [cited 2017 May 7];28(1):e3. Available from: Lee M V., Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, et al. BRCA -associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. RadioGraphics [Internet] May 26 [cited 2017 Jul 10]; Available from: van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HFA, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet [Internet] Sep [cited 2017 Jul 11];42(9): Available from: Strand Life Sciences Pvt. Ltd. 5th Floor, Kirloskar Business Park, Bellary Road, Hebbal, Bangalore Phone: , support.strandx@strandls.com, Strand is accredited by # Certificate No. MC Strand Patient ID: GC Strand Life Sciences
CASE STUDY. Mutation-Specific Testing: Eligibility for PARP Inhibitor Therapy Established. Introduction. Patient Profile.
CASE STUDY Mutation-Specific Testing: Eligibility for PARP Introduction Genetic testing is an emergent diagnostic technique that can provide specific and actionable inputs to the management of cancer therapy.
More informationCASE STUDY. Germline Cancer Testing in A Proband: Extension of Benefits to Unaffected Family Members. Introduction. Patient Profile.
CASE STUDY Germline Cancer Testing in A Proband: Extension of Benefits to Unaffected Family Members Introduction Most cancers are caused by genetic damage resulting from random mutations and exposure to
More informationProactive Patient Paves the Way for Genetic Testing of Eight Family Members
CASE STUDY Proactive Patient Paves the Way for Genetic Testing of Eight Family Members Quick Summary Samar Mohite * was diagnosed with colon adenocarcinoma at the age of 49 years. Genetic counselling was
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationResult Navigator. Positive Test Result: RAD51C. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: RAD51C Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationLearn your genetic risk for the most common hereditary cancers.
Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,
More informationA Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationGenetic testing and pancreatic disease
Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,
More informationThe Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine
The Value of Panel Testing in Inherited Breast Cancer Risk Assessment Rodney J. Scott Division of Molecular Medicine Mutation Detection Next Generation DNA sequencing has revolutionised mutation detection
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling
More informationBRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY
BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationHereditary Cancer Update Strengthening Linkages Workshop April 22, 2017
Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is
More informationUse of panel tests in place of single gene tests in the cancer genetics clinic
Clin Genet 2015: 88: 278 282 Printed in Singapore. All rights reserved CLINICAL GENETICS doi: 10.1111/cge.12488 Short Report se of panel tests in place of single gene tests in the cancer genetics clinic
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationOvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer
patient guide OvaNext genetic testing for hereditary breast, ovarian, and uterine cancer Because knowing your risk can mean early detection and prevention About half of the women diagnosed with uterine
More informationThe Role of genetic Testing for Inherited Prostate Cancer Risk
FOIU July 2018 The Role of genetic Testing for Inherited Prostate Cancer Risk Leonard G. Gomella, MD Chairman, Department of Urology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,
More informationUnderstanding Your Positive Result. A guide to understanding your risk and taking action
Understanding Your Positive Result A guide to understanding your risk and taking action 2017 Myriad Genetics, Inc. 320 Wakara Way, Salt Lake City, Utah 84108 PH: 1-800-469-7423 FX: 801-584-3615 1 PART
More informationGenetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP
Genetics and Cancer Care Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP Faculty/Presenter Disclosure Faculty: Cynthia Forster-Gibson Relationships with commercial interests:
More informationGenetic Determinants, Risk Assessment and Management
Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon
More informationGenetics & Precision Medicine Cancer Care
Genetics & Precision Medicine Cancer Care Johnathan M. Lancaster, MD PhD Chief Medical Officer Myriad Genetics Copyright 2015 Myriad Genetics, Inc., all rights reserved. www.myriad.com. Precision Medicine
More informationGENETIC TESTING FOR HEREDITARY CANCER
UnitedHealthcare Oxford Clinical Policy GENETIC TESTING FOR HEREDITARY CANCER Policy Number: DIAGNOSTIC 004.27 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationpatient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime types
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationTumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in
SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013
Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationA Patient s Guide to. Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer.
More informationBRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI
BRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI DR KIRTI CHADHA MD (Path), PDCC (Oncopath & Oncohemat) CONSULTANT SURGICAL PATHOLOGIST NATIONAL COORDINATOR,SURGICAL PATHOLOGY
More informationResult Navigator Positive Test Result: MSH6
Result Navigator Positive Test Result: MSH6 Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationGenetic testing for hereditary cancer
Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationGenetic Tests for Diagnosis Of Breast Cancer
Your genes know it. Shouldn't you too? Genetic Tests for Diagnosis Of Breast Cancer Your questions answered Introduction Breast cancer is one of the most common cancers in women with most cases occurring
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationUtilization of BRCA Testing. Breast and Ovarian Cancer in Texas
Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationFamily Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool
Besides the BRCA genes, what else to consider in hereditary breast and ovarian cancer? Laurie M. Connors DNP, APNG, FNP-BC, AGN-BC Objectives Evaluate personal & family history to assess risk for hereditary
More informationA pathogenic mutation was identified in the BRCA1 gene.
Hereditary Cancer Risk Test ORDERING PHYSICIAN Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA SPECIMEN Type: Saliva Barcode: 223 234234 2343 Collected: Apr 13, 2016 Received: Apr 14, 2016
More informationGeneHealth BreastGene_New qxp_Layout 1 21/02/ :42 Page 3 BreastGene GeneHealth UK
GeneHealth BreastGene_New 8.2.17.qxp_Layout 1 21/02/2017 16:42 Page 3 BreastGene GeneHealth UK BreastGene What is hereditary breast cancer? Breast cancer is the most common cancer in the UK. Unfortunately
More informationBRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview
BRCA gene Associated Syndrome Name: Hereditary Breast and Cancer syndrome (HBOC) BRCA Summary Cancer Risk Table Male Breast GENETIC RISK Female Breast Elevated Risk Elevated Risk BRCA gene Overview Hereditary
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationCarol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center
Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling
More informationGenetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania
Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationThe Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno
The Role of Genetics in Ovarian Cancer Screening Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno How Much Breast and Ovarian Cancer Is Hereditary? 15%-20% 5%-10% Breast Cancer
More informationI have ovarian cancer
I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (NHS England only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationResult Navigator. Positive Test Result: CDH1. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: CDH1 Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationP NK. Breast Cancer Genetic Risk Test. Test Report
Test Report CONTENTS SECTION 1 1-1. Patient Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Genes Tested SECTION 2 2-1. About the Test 2-2. References 1-1. Patient Information
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationProstateGene What is hereditary prostate cancer? What are genes?
ProstateGene ProstateGene What is hereditary prostate cancer? Prostate cancer is the most common cancer among men in the UK. Unfortunately, 1 in 8 men will be diagnosed with prostate cancer, with 75% being
More informationIncorporating Hereditary Cancer Risk Assessment into Your Practice
Incorporating Hereditary Cancer Risk Assessment into Your Practice DISCLAIMER This information is provided to help answer questions with respect to hereditary cancer risk assessment and hereditary cancer
More informationHereditary Breast and Ovarian Cancers: Risk Management Recommendations. Objectives
Hereditary Breast and Ovarian Cancers: Risk Management Recommendations Tuya Pal, MD Moffitt Cancer Center Objectives 1 Identify genes associated with Hereditary Breast/Ovarian Cancer, including new and
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: CATEGORY: Laboratory Test
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS POLICY NUMBER: 2.02.06 CATEGORY: Laboratory Test EFFECTIVE DATE: 01/17/02 REVISED DATE: 08/21/03, 09/16/04, 08/18/05, 06/15/06, 04/17/14,
More informationBe Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.
Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Hereditary cancer and you Approximately 5% to 10% of all cancers develop because a person inherited a genetic
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationCancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2
AWARD NUMBER: W81XWH-15-1-0084 TITLE: Cancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2 PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationReference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016
Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have
More informationLearning Objectives. Page 1
Learning Objectives 1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation. 2. Explore recent advances in
More informationSo, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.
Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14 REVISED DATE: 10/15/15, 10/20/16, 01/18/18
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY REVISED DATE: 10/15/15, 10/20/16, 01/18/18 PAGE: 1 OF: 10 If a product excludes coverage for a service, it is not covered, and medical policy
More informationpatient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention
patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention Know the Basics Breast cancer is the most common cancer in women
More informationImportance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC
Importance of Family History in Gynecologic Cancer Prevention Angela Thompson, MS, CGC Genetic Counselor Froedtert & The Medical College of Wisconsin Objectives Introduce role of genetic counselor Discuss
More informationCancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor
Cancer Survivorship Symposium Cancer and Heredity January 16, 2017 Jeanne P. Homer, MS Licensed Certified Genetic Counselor Outline Cancer and Heredity Hereditary Cancer Risk Assessment & Genetic testing
More informationGenetic counseling and testing. Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel
Genetic counseling and testing Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau, honoraria, consultancy Astra
More informationPanel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research
Panel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research Malaysia E mail: soohwang.teo@cancerresearch.my How much of
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More informationpatient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationBRCA1 & BRCA2 GeneHealth UK
BRCA1 & BRCA2 GeneHealth UK BRCA1 & BRCA2 What is hereditary breast cancer? Cancer is unfortunately very common, with 1 in 2 people developing cancer at some point in their lifetime. Breast cancer occurs
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? Nancie Petrucelli, MS, CGC Clinical Assistant Professor Certified Genetic Counselor/Coordinator Cancer Genetic Counseling Service Karmanos Cancer Institute Wayne State University
More information